Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Aarhus
With
Aarhus University Hospital
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A mean pulmonary arterial pressure of 25 mmHg measured by right heart catheterization.
A diagnosis of COPD-associated pulmonary hypertension, implicating that no other potential cause of pulmonary hypertension is present.
Stable COPD, defined by no subjective alterations of symptoms or use of short acting beta-antagonists for minimally six weeks. Any exacerbation resulting in admission to hospital or other contacts to a physician must have ceased for at least 6 weeks before entering the study.
Age \> 18
Informed written consent.
Reliable anticonception for fertile women.
You may not be if
Rheumatic disease limiting walking capacity.
Exacerbation in COPD during the study.
Age\>80 years
FEV1 \< 25 % of predicted.
Allergy towards contents of sildenafil or placebo tablets.
Fall in blood pressure of \> 30 mmHg systolic or \>20 mmHg diastolic after intake of the first dose of trial medication.
Fall in peripheral saturation of \> 5% after intake of the first dose of trial medication.
Treatment with nitrous vasodilators or aminophyllamines.
Clareo Health | Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension
